Cargando…
COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment
COVID-19 disease increases interleukin (IL)-1β release. Anti-IL-1-treatment is effective in IL-1-mediated autoinflammatory diseases (AID). This case series presents COVID-19 in patients with IL-1-mediated and unclassified AID with immunosuppressive therapy (IT). Patient 1 is a 34-year-old woman with...
Autores principales: | Welzel, Tatjana, Samba, Samuel Dembi, Klein, Reinhild, van den Anker, Johannes N., Kuemmerle-Deschner, Jasmin B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915607/ https://www.ncbi.nlm.nih.gov/pubmed/33562758 http://dx.doi.org/10.3390/jcm10040605 |
Ejemplares similares
-
Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood
por: Welzel, Tatjana, et al.
Publicado: (2021) -
Colchicine – an effective treatment for children with a clinical diagnosis of autoinflammatory diseases without pathogenic gene variants
por: Welzel, Tatjana, et al.
Publicado: (2021) -
Tapering of biological treatment in autoinflammatory diseases: a scoping review
por: Welzel, Tatjana, et al.
Publicado: (2022) -
Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
por: Welzel, Tatjana, et al.
Publicado: (2021) -
Living with autoinflammatory diseases: identifying unmet needs of children, adolescents and adults
por: Erbis, Gabriele, et al.
Publicado: (2018)